Literature DB >> 30190905

Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy.

Richard Tyrell1, Camila Antia1, Sharon Stanley1, Gary B Deutsch1.   

Abstract

Melanoma is the deadliest form of skin cancer and one of the few malignancies whose incidence is on the rise. The treatment of metastatic melanoma continues to be quite challenging, although in recent years, there has been significant progress. Current National Comprehensive Cancer Network guidelines list immunotherapy, chemotherapy, surgery and clinical trials as potential options for patients with metastatic disease but do not clearly recommend which is superior. Additionally, when utilizing combined modality treatment there are no clear guidelines for the optimal timing of surgery in the treatment of metastatic melanoma. In this paper we sought to compile the current evidence and on-going trials in order to provide a comprehensive review of the different options available and underway in regards to the treatment of metastatic melanoma. It is clear that with the responses now seen with systemic immunotherapies and targeted therapies, an expanded role for surgery is the logical next step.

Entities:  

Keywords:  BRAF; CTLA-4; MEK; PD-1; immune; immunotherapy; melanoma; metastasectomy; metastatic; surgical therapy

Year:  2017        PMID: 30190905      PMCID: PMC6094597          DOI: 10.2217/mmt-2016-0018

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  28 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  Intralesional and systemic immunotherapy for metastatic melanoma.

Authors:  Carrie Luu; Nikhil I Khushalani; Jonathan S Zager
Journal:  Expert Opin Biol Ther       Date:  2016-09-20       Impact factor: 4.388

3.  Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments.

Authors:  Devin C Flaherty; Gary B Deutsch; Daniel D Kirchoff; Jihey Lee; Kelly T Huynh; David Y Lee; Leland J Foshag; Anton J Bilchik; Mark B Faries
Journal:  Am Surg       Date:  2015-10       Impact factor: 0.688

4.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

5.  A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Authors:  Jeffrey A Sosman; James Moon; Ralph J Tuthill; James A Warneke; John T Vetto; Bruce G Redman; P Y Liu; Joseph M Unger; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

Review 6.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes.

Authors:  Nabil Wasif; Sanjay P Bagaria; Partha Ray; Donald L Morton
Journal:  J Surg Oncol       Date:  2011-03-04       Impact factor: 3.454

8.  Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.

Authors:  Wendy K Nevala; Celine M Vachon; Alexey A Leontovich; Christopher G Scott; Michael A Thompson; Svetomir N Markovic
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

Review 9.  Treatment of metastatic melanoma: an overview.

Authors:  Shailender Bhatia; Scott S Tykodi; John A Thompson
Journal:  Oncology (Williston Park)       Date:  2009-05       Impact factor: 2.990

10.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more
  2 in total

1.  A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.

Authors:  Wei Li; Yang Xiao; Xuewen Xu; Yange Zhang
Journal:  Ann Surg Oncol       Date:  2020-11-15       Impact factor: 5.344

Review 2.  Overcoming Immune Evasion in Melanoma.

Authors:  Kevinn Eddy; Suzie Chen
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.